• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

    11/12/24 6:01:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email
    SC 13G/A 1 UnitedStates_13G__TreaceMedi.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* (Name of Issuer) Treace Medical Concepts Inc (Title of Class of Securities) Common Stock (CUSIP Number) 89455T109 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 89455T109 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 89,363 (7) Sole dispositive power 2,610,463 (8) Shared dispositive power 131,025 (9) Aggregate amount beneficially owned by each reporting person 2,741,488 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 4.40% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Treace Medical Concepts Inc Item 1(b) Address of issuer's principal executive offices: 100 Palmetto Park Place Ponte Vedra Beach, FL 32081 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 89455T109 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 2,741,488 (b) Percent of class: 4.40% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 2,741,488 (b) Percent of class: 4.40% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 89,363 (iii) Sole power to dispose or to direct the disposition of: 2,610,463 (iv) Shared power to dispose or to direct the disposition of: 131,025 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
    Get the next $TMCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    5/8/2024$15.00 → $6.00Buy → Hold
    Stifel
    5/8/2024$15.00 → $8.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TMCI
    Financials

    Live finance-specific insights

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec

      2/6/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/4/25 6:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      9/17/24 5:17:19 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      8/19/24 9:00:08 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    SEC Filings

    See more
    • SEC Form S-8 filed by Treace Medical Concepts Inc.

      S-8 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/9/25 8:43:56 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Treace Medical Concepts Inc.

      10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:10:24 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:05:29 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Upcoming Board Chair Transition

      PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace will succeed James T. Treace, who notified the Board that he will retire from the Board when his current term as a director ends at

      4/7/25 8:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/14/24 3:38:23 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/12/24 6:01:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/8/24 3:44:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Treace Medical Concepts upgraded by BTIG Research with a new price target

      BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

      2/4/25 7:10:07 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Treace Medical Concepts with a new price target

      Lake Street initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $14.50

      12/31/24 7:48:21 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Analyst resumed coverage on Treace Medical Concepts with a new price target

      Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00

      12/17/24 8:22:27 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Innovation Officer Scanlan Sean F. exercised 50,000 shares at a strike of $1.05 and sold $398,460 worth of shares (50,000 units at $7.97) (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/19/25 9:30:04 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SVP, Sales Berutti Aaron covered exercise/tax liability with 2,543 shares, decreasing direct ownership by 1% to 209,999 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/11/25 9:00:14 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. covered exercise/tax liability with 7,084 shares, decreasing direct ownership by 0.10% to 6,789,106 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/11/25 9:00:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Treace Appoints Guy Guglielmino as Chief Commercial Officer

      PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

      12/2/24 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

      PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

      8/21/23 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

      PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

      7/12/23 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care